Literature DB >> 23315976

Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells.

Joe Hasei1, Tsuyoshi Sasaki, Hiroshi Tazawa, Shuhei Osaki, Yasuaki Yamakawa, Toshiyuki Kunisada, Aki Yoshida, Yuuri Hashimoto, Teppei Onishi, Futoshi Uno, Shunsuke Kagawa, Yasuo Urata, Toshifumi Ozaki, Toshiyoshi Fujiwara.   

Abstract

Tumor suppressor p53 is a multifunctional transcription factor that regulates diverse cell fates, including apoptosis and autophagy in tumor biology. p53 overexpression enhances the antitumor activity of oncolytic adenoviruses; however, the molecular mechanism of this occurrence remains unclear. We previously developed a tumor-specific replication-competent oncolytic adenovirus, OBP-301, that kills human osteosarcoma cells, but some human osteosarcoma cells were OBP-301-resistant. In this study, we investigated the antitumor activity of a p53-expressing oncolytic adenovirus, OBP-702, and the molecular mechanism of the p53-mediated cell death pathway in OBP-301-resistant human osteosarcoma cells. The cytopathic activity of OBP-702 was examined in OBP-301-sensitive (U2OS and HOS) and OBP-301-resistant (SaOS-2 and MNNG/HOS) human osteosarcoma cells. The molecular mechanism in the OBP-702-mediated induction of two cell death pathways, apoptosis and autophagy, was investigated in OBP-301-resistant osteosarcoma cells. The antitumor effect of OBP-702 was further assessed using an orthotopic OBP-301-resistant MNNG/HOS osteosarcoma xenograft tumor model. OBP-702 suppressed the viability of OBP-301-sensitive and -resistant osteosarcoma cells more efficiently than OBP-301 or a replication-deficient p53-expressing adenovirus (Ad-p53). OBP-702 induced more profound apoptosis and autophagy when compared with OBP-301 or Ad-p53. E1A-mediated miR-93/106b upregulation induced p21 suppression, leading to p53-mediated apoptosis and autophagy in OBP-702-infected cells. p53 overexpression enhanced adenovirus-mediated autophagy through activation of damage-regulated autophagy modulator (DRAM). Moreover, OBP-702 suppressed tumor growth in an orthotopic OBP-301-resistant MNNG/HOS xenograft tumor model. These results suggest that OBP-702-mediated p53 transactivation is a promising antitumor strategy to induce dual apoptotic and autophagic cell death pathways via regulation of miRNA and DRAM in human osteosarcoma cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23315976     DOI: 10.1158/1535-7163.MCT-12-0869

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  29 in total

Review 1.  Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments.

Authors:  H Inoue; K Tani
Journal:  Cell Death Differ       Date:  2013-07-05       Impact factor: 15.828

2.  Modulation of p53 expression in cancer-associated fibroblasts prevents peritoneal metastasis of gastric cancer.

Authors:  Toshihiro Ogawa; Satoru Kikuchi; Motoyasu Tabuchi; Ema Mitsui; Yuta Une; Hiroshi Tazawa; Shinji Kuroda; Kazuhiro Noma; Toshiaki Ohara; Shunsuke Kagawa; Yasuo Urata; Toshiyoshi Fujiwara
Journal:  Mol Ther Oncolytics       Date:  2022-04-25       Impact factor: 6.311

3.  Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.

Authors:  M Takagi-Kimura; T Yamano; M Tagawa; S Kubo
Journal:  Cancer Gene Ther       Date:  2014-02-28       Impact factor: 5.987

4.  Expression of p53 synergistically augments caspases-mediated apoptosis induced by replication-competent adenoviruses in pancreatic carcinoma cells.

Authors:  Y Takei; S Okamoto; K Kawamura; Y Jiang; T Morinaga; M Shingyoji; I Sekine; S Kubo; Y Tada; K Tatsumi; H Shimada; K Hiroshima; N Yamaguchi; M Tagawa
Journal:  Cancer Gene Ther       Date:  2015-08-07       Impact factor: 5.987

5.  Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma.

Authors:  Yusuke Mochizuki; Hiroshi Tazawa; Koji Demiya; Miho Kure; Hiroya Kondo; Tadashi Komatsubara; Kazuhisa Sugiu; Joe Hasei; Aki Yoshida; Toshiyuki Kunisada; Yasuo Urata; Shunsuke Kagawa; Toshifumi Ozaki; Toshiyoshi Fujiwara
Journal:  Cancer Immunol Immunother       Date:  2020-11-05       Impact factor: 6.968

6.  Cytotoxic effects of replication-competent adenoviruses on human esophageal carcinoma are enhanced by forced p53 expression.

Authors:  Shan Yang; Kiyoko Kawamura; Shinya Okamoto; Suguru Yamauchi; Masato Shingyoji; Ikuo Sekine; Hiroshi Kobayashi; Yuji Tada; Koichiro Tatsumi; Kenzo Hiroshima; Hideaki Shimada; Masatoshi Tagawa
Journal:  BMC Cancer       Date:  2015-06-10       Impact factor: 4.430

7.  Up-Regulation of MiR-300 Promotes Proliferation and Invasion of Osteosarcoma by Targeting BRD7.

Authors:  Zhen Xue; Jindong Zhao; Liyuan Niu; Gang An; Yashan Guo; Linying Ni
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

8.  The Downregulation of MiR-182 Is Associated with the Growth and Invasion of Osteosarcoma Cells through the Regulation of TIAM1 Expression.

Authors:  Jun Hu; Guohua Lv; Shuguang Zhou; Yucheng Zhou; Bangxu Nie; Hong Duan; Yunfeng Zhang; Xiaofeng Yuan
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

9.  Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.

Authors:  Kazuhisa Sugiu; Hiroshi Tazawa; Joe Hasei; Yasuaki Yamakawa; Toshinori Omori; Tadashi Komatsubara; Yusuke Mochizuki; Hiroya Kondo; Shuhei Osaki; Tomohiro Fujiwara; Aki Yoshida; Toshiyuki Kunisada; Koji Ueda; Yasuo Urata; Shunsuke Kagawa; Toshifumi Ozaki; Toshiyoshi Fujiwara
Journal:  Cancer Chemother Pharmacol       Date:  2021-06-10       Impact factor: 3.333

10.  An MDM2 inhibitor achieves synergistic cytotoxic effects with adenoviruses lacking E1B55kDa gene on mesothelioma with the wild-type p53 through augmenting NFI expression.

Authors:  Thao Thi Thanh Nguyen; Masato Shingyoji; Michiko Hanazono; Boya Zhong; Takao Morinaga; Yuji Tada; Hideaki Shimada; Kenzo Hiroshima; Masatoshi Tagawa
Journal:  Cell Death Dis       Date:  2021-07-02       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.